37 search results for “Immunology”

We believe that progress and success in research can only be achieved by a highly diverse community of like-minded outstanding scientists. Sharing ideas and helping each other is key.

The project’s cores are to develop a ligand specific for a target cell and establish quantitative assessment methods to monitor macromolecular drug delivery across the intestinal epithelial barrier.

The core of the project will be the development of a first in kind synovium-in-a-dish assay for systematic monitoring of macrophage functions.

Our management and project teams are regularly represented at events and report there about BioMed X and our ongoing research.

For us at BioMed X, publishing the results of our research projects in peer-reviewed journals is key. We also share results at national and international meetings and workshops. We think this is vital to building collaborations and stimulating cross-fertilization of ideas and methods.

At the BioMed X Institute, we are working with different state-of-the-art research tools and methods, emerging from the different research projects. As a Special Interest Group, we continuously grow our internal spectrum of laboratory tools and methods.

Fellowships at BioMed X are limited to a defined project term. During this period, all fellows focus their attention on biomedical research as well as personal growth in order to get ready for their next big challenge in academia, industry or a startup. The Special Interest Group “Career Development” is a grassroots initiative of BioMed X fellows organizing events and training courses.

Completed Projects · Oncology Team IMT Immunosuppressive Microenvironment of Tumors Solid tumors are complex microenvironments composed of cancer and immune cells that interact through various regulatory networks. Although CD8 T-cells may recognize and kill tumor cells, their function is impaired by cells such as regulatory T-cells, tumor-associated macrophages (TAM), and myeloid-derived suppresso …

The main objective of the IEB group is to identify key molecular mechanisms at intestinal epithelial-immune cells interface, in order to identify and develop new therapeutic targets for intestinal barrier loss in autoimmune diseases that will improve patient outcomes.

The team is seeking new platform technologies or concepts which lead to identification of antigens recognized by T cells involved in autoimmune responses.

The team is interested in identifying key molecular and cellular mechanisms at the pathogen-host interface which could be exploited as potential targets for the treatment of multiple chronic inflammatory diseases.